Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sionna Therapeutics, Inc. - Common Stock (NQ:SION)

36.91 +0.43 (+1.18%)
Streaming Delayed Price Updated: 1:56 PM EDT, Jun 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 144,617
Open 36.50
Bid (Size) 36.61 (100)
Ask (Size) 37.05 (100)
Prev. Close 36.48
Today's Range 35.66 - 37.25
52wk Range 13.33 - 48.45
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-5.9%
-5.9%
1 Month
-8.8%
-8.8%
3 Month
+8.3%
+8.3%
6 Month
-5.4%
-5.4%
1 Year
+164.2%
+164.2%

More News

Read More
News headline image
Sionna Therapeutics Reports First Quarter 2026 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should Watch ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch ↗
Via The Motley Fool
News headline image
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares ↗
Via The Motley Fool
News headline image
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Chief Legal Officer Caps Off Strong 2025 with Sale of Over 10,000 Shares ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Sionna Therapeutics to Participate in Upcoming December Investor Conferences
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Reports Third Quarter 2025 Financial Results
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Participate in Upcoming November Investor Conferences
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference
From Sionna Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer
From Sionna Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Sionna Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sionna Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sionna Therapeutics, Inc. - Common Stock trade on?
Sionna Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sionna Therapeutics, Inc. - Common Stock?
The ticker symbol for Sionna Therapeutics, Inc. - Common Stock is SION on the Nasdaq Stock Market
What is the current price of Sionna Therapeutics, Inc. - Common Stock?
The current price of Sionna Therapeutics, Inc. - Common Stock is 36.91
When was Sionna Therapeutics, Inc. - Common Stock last traded?
The last trade of Sionna Therapeutics, Inc. - Common Stock was at 06/03/26 01:56 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.